Cadila Healthcare Limited

Company overview. Cadila Healthcare Limited is the former legal name of Zydus Lifesciences Limited, an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1952 by Ramanbhai Patel; the group was restructured in 1995 into Cadila Healthcare under the Zydus umbrella, and the company was renamed Zydus Lifesciences in February 2022. It is publicly listed in India (NSE/BSE; formerly ticker CADILAHC, now ZYDUSLIFE) and is not a subsidiary. Wikipedia/company filings place FY2025 consolidated revenue at roughly ₹23,242 crore (about US$2.7–2.8 billion) with 25,000–28,000 employees; the US generics arm operates as Zydus Pharmaceuticals (USA) Inc.

Products / services / operations. Zydus is an operating, fully integrated pharma company — not an NPE. It runs two reporting segments: Pharmaceuticals (~87% of revenue) and Consumer Products (~13%). Offerings include generics and branded formulations (India and US), complex generics and 505(b)(2) products, biosimilars and vaccines, active pharmaceutical ingredients (APIs), and animal health/veterinary products. The US business is its largest single market, driven by ANDA filings and launches; India branded formulations focus on cardiology, diabetes, respiratory, oncology and nephrology. Consumer wellness brands include Complan, Glucon-D, Sugar Free, Everyuth and Nycil. It operates 30-plus manufacturing plants and sells in roughly 55 countries.

Patent-litigation posture. The tracked data shows a single case, with the company as defendant and zero as plaintiff — the profile of an operating company defending, not an assertion-driven NPE. The suit was filed in the District of New Jersey, a common venue for pharmaceutical Hatch-Waxman/ANDA disputes, not a plaintiff-friendly NPE district such as the Eastern District of Texas. This is consistent with Zydus's position as a generic manufacturer frequently named in patent suits by branded drugmakers.

Notable cases. The only tracked matter is Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al. (D.N.J., filed 2018-04-27), in which Cadila/Zydus entities appear as defendants alongside the US subsidiary. The case reflects the company's US generics exposure to brand-holder patent enforcement. No further tracked filings are recorded, and no litigation-funding or assertion-entity characteristics apply.